Stryker Corporation (SYK) Analyst Ratings & Price Targets

Stryker Corporation

SYK · NYSE

Analyst Consensus

Buy

24 analysts

$310

Current

$340

Low

$339

Average

$400

High

Average target implies +9.53% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 24 analysts. Price targets range from $340 to $400, a $60 spread, with a mean of $360; the evidence does not provide a target distribution or identify the analysts at either end. Accordingly, the $400 target is the most bullish and the $340 target the least bullish in the snapshot, but their firms and analysts cannot be named. No rating or target revisions are included for the past week, so the direction of weekly revisions is not established. The measurable disagreement is the breadth of the target range despite a uniformly Buy consensus; the supplied evidence does not explain the assumptions behind that spread.

Rating Actions

2 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Truist Financial	—	Hold Raised price target	$340from $330	+9.9%	Jul 31, 2026	Open the report this row came from
UBS	—	Unrated Set price target	$400	+29.2%	Feb 24, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BTIG

CITIGROUP

CO FORECST

DEUTSCHE BK SEC

EDWARD JONES

JEFFERIES & CO.

JP MORGAN SECUR

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

ROTH CAPITAL PA

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: SYK
Type: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Country: North America
Exchange: NYSE

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com .

Key Issues

Bullish view

The second quarter showed 9% organic sales growth and 17.9% adjusted EPS growth, indicating that sales momentum is returning after the cybersecurity disruption and can support renewed operating leverage.

Bearish view

Management narrowed 2026 guidance despite the earnings beat, suggesting that the recovery may be less complete or less predictable than the headline results imply.

Analyst Consensus

See all

Buy

24 analysts

$310

Current

$340

Low

$339

Average

$400

High

Average target implies +9.53% versus the current price.

Earnings History

BeatMissNo estimate

Stryker Corporation

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers